Panzem
information and resources from the National Cancer Institute
Panzem
(Other name for: 2-methoxyestradiol)Panzem
(Other name for: 2-methoxyestradiol)
|
|
|
|
news articles
EntreMed Gets License for Panzem Patent Mar 16, 2006
MSN Money ...said Thursday that it has exclusively licensed a patent covering its lead drug candidate Panzem NCD from Children's Hospital Boston. ...
NewsWatch: Wildlife charming but costly to farmers Mar 17, 2006
Business Gazette, 7,012,070 for its Panzem oral compound, currently in phase 2 clinical trials, for cancer treatment. Panzem is also in preclinical ...
EntreMed announces new US Patent - "Estrogenic Compounds as Anti ... Mar 17, 2006
News-Medical.net, Panzem NCD, an oral formulation of 2ME2, is currently in Phase 2 clinical trials for cancer. Panzem is also in preclinical development ...
EntreMed Reports Fourth Quarter and Year-End 2005 Financial ... Mar 7, 2006
PharmaLive.com (press release), ...from prior quarters related to the procurement of bulk drug material and formulation services to support current and planned clinical studies for Panzem(R) NCD ...
EntreMed gets new patent for novel compound Mar 17, 2006
Pharmaceutical Business Review ...worldwide to EntreMed. Panzem NCD, an oral formulation of 2ME2, is currently in phase II clinical trials for cancer. EntreMed is ...
EntreMed to Present at the BioCentury Future Leaders in the ... Mar 27, 2006
Yahoo! News (press release) Panzem® (2-methoxyestradiol or 2ME2), the Company's lead drug candidate, is currently in Phase 2 clinical trials for cancer, as well as in preclinical ...
New 2ME2 Patent Strengthens EntreMed's Position in Cancer and Non ... Mar 16, 2006
PR Newswire (press release), Panzem(R) NCD, an oral formulation of 2ME2, is currently in Phase 2 clinical trials for cancer. Panzem(R) is also in preclinical ...
Drug stocks mixed; Cephalon falls on drug concerns Mar 16, 2006
Investor's Business Daily (subscription) The biotech group announced it had received a patent covering methods of treatment for its oncology drug candidate, 2ME2, also known as Panzem. ...
EntreMed Receives New Panzem Patent Dec 7, 2005
MSN Money ...said Wednesday that the Patent and Trademark Office issued it a new patent that extends protection on its experimental cancer treatment Panzem NCD. ...
EntreMed Receives Composition of Matter Patent Claims for 2ME2 Dec 7, 2005
PR Newswire (press release), 2ME2 is currently in clinical trials for cancer (Panzem(R) Capsules and Panzem(R) NCD), as well as in preclinical development for rheumatoid arthritis. ...
EntreMed gets FDA approval for cancer drug tests Nov 22, 2005
Washington Business Journal, EntreMed says the Food and Drug Administration has approved its application to begin testing a modified version of its flagship cancer-fighting drug Panzem. ...
EntreMed Announces FDA Acceptance of IND Application for ENMD-1198 Nov 22, 2005
PharmaLive.com (press release), Last week, we announced results from our Phase Ib trials with our lead drug candidate, 2ME2 (Panzem(R) NCD) and the planning of Phase II studies. ...
EntreMed and Affymax Present Preclinical Data for Novel ... Dec 13, 2005
PR Newswire (press release), Panzem(R) (2-methoxyestradiol or 2ME2), the Company's lead drug candidate, is currently in clinical trials for cancer, as well as in preclinical development ...
|
|
